The goal of the Facilities and Biosafety Core Facility is to provide a safe, well-maintained, well-equipped research infrastructure that promotes efficient, effective collaborative cancer research. This Core Facility has two major components: Facilities and Biosafety. The Facilities component provides two major oversight services, including responsibility for: (1) oversight of common equipment and training users of common equipment; and, (2) building operations and renovation/repair. The Biosafety component provides a safe working environment and appropriate training for members who need to work with hazardous infectious agents. Services include providing containment space for researchers working with primate lentiviruses (HIV-1 and SIV), to provide containment space for the propagation and purification of infectious DNA clones, to provide containment space for researchers working with human tumor tissue, and to provide containment space for a DNMPCR clean working environment for the processing of tissue samples prior to PeR amplification. Highlights of research supported by the Biosafety component : the use of human thymus cultures to explore questions of HIV-1 pathogenesis (Lishan Su), the analysis of human and macaque blood plasma samples to examine the natural history of HIV-1 and SIV during primary infection (Ronald Swanstrom), and the study of the pathogenesis of herpesviruses in HIV-1 infected patients (Jennifer Webster-Cyriaque).. The Facilities Component services the 80,000 net square foot Lineberger Cancer Center Building, which houses about 55 faculty investigators,/projects, nine core facilities, and common equipment and space, and Administration. The Facilities component helps the Center maintains over 450 pieces of equipment in 23 common rooms. This dual component shared resource makes possible a safe, well-maintained, and efficient research facility. The Biosafety Containment component is essential to investigators working with biohazardous materials and is not readily available elsewhere.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-31
Application #
7310747
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
31
Fiscal Year
2006
Total Cost
$53,235
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications